Scientific publications

2019

Almasi T, Guey LT, Lukacs C, Csetneki K, Voko Z, Zelei T. Systematic literature review and meta-analysis on the epidemiology of methylmalonic acidemia(MMA) with a focus on MMA caused by methylmalonyl-CoA mutase (mutdeficiency. Orphanet J Rare Dis. 2019 Link

Agh T, Csanadi M, Voko Z, Webb T, Jeyakumaran D, Trudeau J, Sengupta N, Schain F, Mattsson J. Humanistic burden of patients with chronic graft-versus-host disease - systematic literature review of health-related quality of life and functional status.Expert Rev Hematol. 2019 Mar 29. [Epub ahead of print] Link

Csanadi M, Agh T, Tordai A, Webb T, Jeyakumaran D, Sengupta N, Schain F, Mattsson J. A systematic literature review of incidence, mortality and relapse of patients diagnosed with chronic graft versus host disease. Expert Rev Hematol. 2019 Apr 6. [Epub ahead of print] Link

Szilberhorn, L., Korosi, L., Vajer, P., Nagy, B., & Voko, Z. Cost-effectiveness of introducing licensed GP practices to manage diabetes patients in Hungary. Primary Care Diabetes. (2019) Link

Pitter JG, Csanadi M, Szigeti A, Lukacs G, Kovacs A, Moizs M, Repa I, Zemplenyi A, Czypionka T, Kraus M, Rutten-van Mölken MPMH, Kalo Z. Planning, implementation and operation of a personalized patient management system for subjects with first suspect of cancer (OnkoNetwork): system description based on a qualitative study. BMC Health Serv Res. 2019 Feb 21;19(1):131. Link 

Nemeth B, Bendes R, Nagy B, Gotze A, Koczian K, Horvath M, Deak I, Toth B, Kalo Z. Cost-utility analysis of cariprazine compared to risperidone among patients with negative symptoms of schizophrenia. Health Policy and Technology [AHEAD OF PRINT] (2019). Link

Nemeth B, Molnar A, Bozoki S, Wijaya K, Inotai A, Campbell J, Kalo Z. Comparison of weighting methods used in multicriteria decision analysis frameworks in healthcare with focus on low- and middle-income countries. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH [AHEAD OF PRINT] (2019) Link

Almasi T, Guey TL, Lukacs C, Csetneki K, Voko Z, Zelei T. Systematic literature review and meta-analysis on the epidemiology of propionic acidemia. ORPHANET JOURNAL OF RARE DISEASES 2019,14:40 Link

Pednekar PP, Ágh T, Malmenäs M, Raval AD, Bennett BM, Borah BJ, Hutchins DS, Manias E, Williams AF, Hiligsmann M, Turcu-Stiolica A, Zeber JE, Abrahamyan L, Bunz TJ, Peterson AM: Methods for Measuring Multiple Medication Adherence: A Systematic Review–Report of the ISPOR Medication Adherence and Persistence Special Interest Group. Value Health 2019, 22:139-156. Link

Csanadi M, de Kok IM, Heijnsdijk EA, Anttila A, Heinävaara S, Pitter JG, Szeles G, Ivanuš U, Priaulx J, Veerus P, Senore C, Koning HJ, Voko Z. Key indicators of organized cancer screening programs: Results from a Delphi study. JOURNAL OF MEDICAL SCREENING (2019) Link

Szilberhorn L, Kalo Z, Agh T. Cost-effectiveness of second-generation direct-acting antiviral agents in chronic HCV infection: a systematic literature  review. ANTIVIR THER.  (2019) Link 

 

2018

Inotai A, Brixner D, Maniadakis N, Dwiprahasto I, Kristin E, Prabowo A, Yasmina A, Priohutomo S, Nemeth B, Wijaya K, Kalo Z. Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals - an application on improving tender decision making in Indonesia. BMC HEALTH SERV RES 18(1):1003. (2018) Link

Gyulai A, Nagy A, Pataki V, Tonte D, Adany R, Voko Z. General practitioners can increase participation in cervical cancer screening – a model program in Hungary. BMC FAMILY PRACTICE 19:(1) Paper 67. 8 p. (2018) Link

Pitter J G, Voko Z, Jozwiak A, Berkics A. Campylobacter control measures in indoor broiler chicken: critical re-assessment of cost-utility and putative barriers to implementation. EPIDEMIOLOGY AND INFECTION -:(-) pp. 1-12. (2018) Link

Turnbull E, Priaulx J, van Ravesteyn NT, Heinävaara S, Siljander I, Senore C, Segnan N, Voko Z, Hagymasy J, Jarm K, Veerus P, de Koning HJ, McKee M. A health systems approach to identifying barriers to breast cancer screening programmes. Methodology and application in six European countries. Health Policy. 2018 Nov;122(11):1198-1205. Link

Turnbull E, Priaulx J, de Kok IMCM, Lansdorp-Vogelaar I, Anttila A, Sarkeala T, Senore C, Segnan N, Csanádi M, Pitter J, Novak Mlakar D, Ivanus U, Veerus P, de Koning HJ, McKee M. Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. Health Policy. 2018 Nov;122(11):1206-1211.Link 

Priaulx J, de Koning HJ, de Kok IMCM, Széles G, McKee M. Identifying the barriers to effective breast, cervical and colorectal cancer screening in thirty one European countries using the Barriers to Effective Screening Tool (BEST). HEALTH POLICY. Nov;122(11):1190-1197. (2018) Link 

Csanadi M, Harsanyi A, Ozieranski P, Loblova O, Kalo Z, King L, McKee M. When health technology assessment is confidential and experts have no power: the case of Hungary. HEALTH ECONOMICS, POLICY AND LAW. Link

Inotai A, Agh T, Karpenko AW, Zemplenyi A, Kalo Z. Behind the Subcutaneous Trastuzumab Hype: Evaluation of Benefits and Their Transferability to Central Eastern European Countries. EXPERT REV PHARMACOECON OUTCOMES RES. (2018) Link

Bochenek T, Abilova V, Alkan A, Asanin B, de Miguel Beriain I, Besovic Z, Vella Bonanno P, Bucsics A, Davidescu M, De Weerdt E, Duborija-Kovacevic N, Furst J, Gaga M, Gailīte E, Gulbinovič J, Gurpınar EU, Hanko B, Hargaden V, Hotvedt TA, Hoxha I, Huys I, Inotai A, Jakupi A, Jenzer H, Joppi R, Laius O, Lenormand MC, Makridaki D, Malaj A, Margus K, Marković-Peković V, Miljković N, de Miranda JL, Primožič S, Rajinac D, Schwartz DG, Šebesta R, Simoens S, Slaby J, Sović-Brkičić L, Tesar T, Tzimis L, Warmińska E, Godman B. Systemic Measures and Legislative and Organizational Frameworks Aimed at Preventing or Mitigating Drug Shortages in 28 European and Western Asian Countries. FRONT PHARMACOL. (2018) Link

Inotai A, Nguyen HT, Hidayat B, Nurgozhin T, Kiet PHT, Campbell JD, Nemeth B, Maniadakis N, Brixner D, Wijaya K, Kalo Z. Guidance towards the Implementation of Multi-Criteria Decision Analysis Framework in Developing Countries: Lessons Learned from Pilot Policy Research Projects to Apply MCDA for Off-Patent Pharmaceuticals in Indonesia, Kazakhstan and Vietnam. EXPERT REV PHARM OUTCOME RES 18(6):585-592. (2018) Link

Szegedi M, Zelei T, Arickx F, Bucsics A, Zanchetta EC, Furst J, Kamusheva M, Kawalec P, Petrova G, Slaby J, Stawowczyk E, Vocelka M, Zechmeister Koss I, Kalo Z, Molnar MJ. The European challenges of funding orphan medicinal products. ORPHANET JOURNAL OF RARE DISEASES 6;13(1):184. (2018) Link

Campbell JD, Kalo Z. Fair Global Drug Pricing. EXPERT REV PHARM OUTCOME RES18(6):581-583. (2018) Link

Kamusheva M, Manova M, Savova AT, Petrova GI, Mitov K, Harsanyi A, Kalo Z, Marky K, Kawalec P, Angelovska B, Lakić D, Tesar T, Draganic P, Geitona M, Hatzikou M, Paveliu MS, Männik A. Comparative analysis of legislative requirements about patients’ access to biotechnological drugs for rare diseases in Central and Eastern European Countries. FRONTIERS IN PHARMACOLOGY. (2018) Link

Nestler-Parr S, Korchagina D, Toumi M, Pashos CL, Blanchette C, Molsen E, Morel T, Simoens S, Kalo Z, Gatermann R, Redekop K. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group. VALUE IN HEALTH 21. 5. 493–500. (2018) Link

Kolasa K, Zwolinski KM, Zah V, Kalo Z, Lewandowski T. Revealed preferences towards the appraisal of orphan drugs in Poland - multi criteria decision analysis. ORPHANET J RARE DIS 27;13(1):67. (2018) Link

Brixner D, Kalo Z, Maniadakis N, Wijaya K. An Evidence Framework for Off-Patent Pharmaceutical Review (EFOR) for Health Technology Assessment in Emerging Markets. VALUE IN HEALTH REGIONAL ISSUES 29. 16. 9-13. (2018) Link

Fasseeh A, Nemeth B, Molnar A, Fricke FU, Horvath M, Koczian K, Gotze A, Kalo Z. A systematic review of the indirect costs of schizophrenia in Europe. EUROPEAN JOURNAL OF PUBLIC HEALTH 28(6), 1043-1049. (2018) Link

Freijer K, Volger S, Pitter JG, Molsen-David E, Cooblall C, Evers et al. (2018). Medical Nutrition Terminology and Regulations in the United States and Europe—A Scoping Review: Report of the ISPOR Nutrition Economics Special Interest Group. VALUE IN HEALTH. (2018) Link

Begum M, Lewison G, Jassem J, Mixich V, Cufer T, Nurgozhin T, Shabalkin P, Kutluk T, Voko Z, Radosavljevic D, Vrdoljiak E, Eniu A, Walewski J, Aggarwal A, Lawler M, Sullivan R. Mapping cancer research across Central and Eastern Europe, the Russian Federation and Central Asia: Implications for future national cancer control planning. EUR J CANCER Oct 19;104:127-136. (2018) Link

Rutten-van Molken M, Leijten F, Hoedemakers M, Tsiachristas A, Verbeek N, Karimi M, Bal R, de Bont A, Islam K, Askildsen JE, Czypionka T, Kraus M, Huic M, Pitter JG, Vogt V, Stokes J1, Baltaxe E. Strengthening the evidence-base of integrated care for people with multi-morbidity in Europe using Multi-Criteria Decision Analysis (MCDA). BMC HEALTH SERV RES Jul 24;18(1):576. (2018) Link

Nemeth B. Health Economics in Hungary: Great potential, missed opportunity? [in Hungarian] LAM (LEGE ARTIS MEDICINÆ) 28(06-07). (2018) Link 

Csanadi M, Kalo Z, Prins CPJ, Grelinger E, Menczelne Kiss A, Fricke FU, Fuksa L, Tesar T, Manova M, Lorenzovici L, Voko L, Garrison LP. The implications of external price referencing on pharmaceutical list prices in Europe. HEALTH POLICY AND TECHNOLOGY 7(3): 243-250. (2018) Link

Leijten FRM, Hoedemakers M, Struckmann V, Kraus M, Cheraghi-Sohi S, Zemplenyi A, Ervik R, Vallve C, Huiĉ M, Czypionka T, Boland M, Rutten-van Molken MPMH; SELFIE consortium. Defining good health and care from the perspective of persons with multimorbidity: results from a qualitative study of focus groups in eight European countries. BMJ OPEN Aug 30;8(8). (2018) Link

Agh T, Gaspar K, Nagy B, Lehmann M, Kalo Z. The value of a child born in the European Union. ACTA OECONOMICA 68(2): 295-309. (2018) Link

Zelei T, Csetneki K, Voko Z, Siffel C. Epidemiology of Sanfilippo syndrome: results of a systematic literature review. ORPHANET J RARE DIS Apr 10;13(1):53. (2018) Link

Csanadi M, Loblova O, Ozieranski P, Harsanyi A, Kalo Z, McKee M, King L. When health technology assessment is confidential and experts have no power: the case of Hungary. HEALTH ECON POLICY LAW Mar 26:1-20. (2018) Link

Kulchaitanaroaj P, Kalo Z, West R, Cheung KL, Evers S, Voko Z, Hiligsmann M, de Vries H, Owen L, Trapero-Bertran M, Leidl R, Pokhrel S. Understanding perceived availability and importance of tobacco control interventions to inform European adoption of a UK economic model: a cross-sectional study. BMC HEALTH SERVICES RESEARCH 14.18(1):115. (2018) Link

Kovacs G, Almasi T, Millier A, Toumi M, Horvath M, Koczian K, Gotze A, Kalo Z, Zemplenyi AT. Direct healthcare cost of schizophrenia–European overview. EUROPEAN PSYCHIATRY 48. 79-92. (2018) Link

Zemplenyi AT, Kalo Z, Kovacs G, Farkas R, Beothe T, Banyai D, Sebestyen Z, Endrei D, Boncz I, Mangel L. Cost-effectiveness analysis of intensity-modulated radiation therapy with normal and hypofractionated schemes for the treatment of localised prostate cancer. EUR J CANCER CARE (Engl). (2018) Link

Inotai A, Csanadi M, Petrova G, Dimitrova M, Bochenek T, Tesar T, York K, Fuksa L, Kostyuk A, Lorenzovici L, Omelyanovskiy V, Egyed K, Kalo Z. Patient access, Unmet medical need, Expected benefits and concerns related to the utilisation of biosimilars in Eastern European Countries: A survey of experts. BIOMED RESEARCH INTERNATIONAL. (2018) Link

Nemeth B, Jozwiak-Hagymasy J, Kovacs G, Kovacs A, Demjen T, Huber M, Cheung KL, Coyle K, Lester-George A, Pokhrel S, Voko Z.Cost-effectiveness of possible future smoking cessation strategies in Hungary: results from the EQUIPTMOD. ADDICTION. (2018) Link

Nemeth B, Fasseeh A, Molnar A, Bitter I, Horvath M, Koczian K, Gotze A, Nagy B. A systematic review of health economic models and utility estimation methods in schizophrenia. EXPERT REV PHARMACOECON OUTCOMES RES Jan 27:1-9. (2018) Link

Nemeth B, Kulchaitanaroaj P, Lester-George A, Huic M, Coyle K, Coyle D, Pokhrel S, Kalo Z. A utility of model input uncertainty analysis in transferring tobacco control-related economic evidence to countries with scarce resources: results from the EQUIPT study. ADDICTION. (2018) Link

Trapero‐Bertran M, Muñoz C, Coyle K, Coyle D, Lester‐George A, Leidl R, Nemeth B, Cheung KL, Pokhrel S, Lopez‐Nicolas A. Cost‐effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD. ADDICTION. (2018) Link

Pitter JG, Lukacs G, Csanadi M, Voko, Z. Clinical impact of treatment delay in pancreatic cancer patients revisited. INT. J. CANCER. (2018) Link

Ozieranski P, Loblova O, Nicholls N, Csanadi M, Kalo Z, McKee M, King L. Transparency in practice: Evidence from 'verification analyses' issued by the Polish Agency for Health Technology Assessment in 2012-2015. HEALTH ECON POLICY LAW. 2018 Link 

Priaulx J, Csanádi M, de Koning HJ, McKee M. A choice experiment to identify the most important elements of a successful cancer screening program according to those who research and manage such programs. INTERNATIONAL JOURNAL OF HEALTH PLANNING AND MANAGEMENT.  (2018) Link

2017

Tesar T, Szilberhorn L, Nemeth B, Nagy B, Wawruch M, Kalo Z. Cost-Utility Analysis of Heberprot-P as an Add-on Therapy to Good Wound Care for Patients in Slovakia with Advanced Diabetic Foot Ulcer. FRONTIERS IN PHARMACOLOGY. (2017) Link

G. Pitter J, Horvath B, Abonyi-Toth Zs, Rokszin Gy, Fadgyas-Freylere P, Kovacs G, Acs N, Kalo Z, Voko Z. Drug-associated miscarriage, teratogenicity and low birthweight risks: Methods for population-based case–control studies in Hungary. REPRODUCTIVE TOXICOLOGY 72: p. 26. (2017) Link

Voko Z, Gaspar K, Inotai A, Horvath Cs, Bors K, Speer G, Kalo Z. Osteoporotic fractures may impair life as much as the complications of diabetes. JOURNAL OF EVALUATION IN CLINICAL PRACTICE 23. 6. 1375-1380. (2017) Link

Molnar A, Nagy B, Kerpel-Fronius A, Bajzik G, Horvath I, Moizs M, Voko Z. Modelling Patient Pathways Of Low-Dose Computed Tomography Screening For Lung Cancer In Hungary. VALUE IN HEALTH 20:(9) p. A750. (2017) Link

Kawalec P, Tesar T, Vostalova L, Draganic P, Manova M, Savova A, Petrova G, Rugaja Z, Männik A, Sowada C, Stawowczyk E, Harsanyi A, Inotai A, Turcu-Stiolica A, Gulbinovič J, Pilc A. Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. FRONT PHARMACOL. (2017) Link

Narbutas Š, York K, Stein BD, Magsanoc-Alikpala K, Majima Y, Kalo Z, Almasi T, Inotai A. Overview on patient centricity in cancer care. FRONTIERS IN PHARMACOLOGY 5. 8. 698. (2017) Link

Nagy B, Setyawan J, Coghill D, Soroncz-Szabo T, Kalo Z, Doshi JA. A conceptual framework for a long-term economic model of the treatment of attention-deficit/hyperactivity disorder. EXPERT REV PHARMACOECON OUTCOMES RES 17. 3. 283-292. (2017) Link

Kalo Z, Abonyi-Toth Zs, Rokszin Gy, Agh T, Inotai A. Impact of multiple switching on health care costs and outcomes in generic drug policies: the Hungarian case of losartan. ACTA POLONIAE PHARMACEUTICA - DRUG RESEARCH 74. 4. 1295-1300. (2017) Link

Kalo Z, Voko Z, Ostor A, Clifton-Brown E, Vasilescu R, Gibson E, Begum N. Patient access to reimbursed biologic disease modifying antirheumatic drugs in the European region. JOURNAL OF MARKET ACCESS & HEALTH POLICY. (2017) Link

Brixner D, Maniadakis N, Kalo Z, Hu S, Shen J, Wijaya K. Applying Multi-Criteria Decision Analysis (MCDA) Simple Scoring as an evidence-based HTA methodology for evaluating off-patent pharmaceuticals (OPPs) in emerging markets. VALUE IN HEALTH REGIONAL ISSUES 13. 1-6. (2017) Link

Rosselli D, Lazo CQ, Csanadi M, Ruiz de Castilla EM, Gonzalez NC, Valdes J, Abicalaffe C, Garzon W, Leon G, Kalo Z. HTA implementation in Latin American countries: Comparison of current and preferred status. VALUE IN HEALTH REGIONAL ISSUES 14. 20-27. (2017) Link

Inotai A, Csanadi M, Harsanyi A, Nemeth B. Drug Policy in Central Eastern Europe—Hungary. VALUE IN HEALTH REGIONAL ISSUES 13:16-22. (2017) Link

Inotai A, Csanadi M, Vitezic D, Francetic I, Tesar T, Bochenek T, Lorenzovici L, Dylst P, Kalo Z. Policy Practices to Maximise Social Benefit from Biosimilars. BIOEQUIV AVAILAB 9 (4):467-472. (2017) Link

Inotai A, Prins CPJ, Csanadi M, Vitezic D, Codreanu C, Kalo Z. Is there a reason for concern or is it just hype? – A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. EXPERT OPIN BIOL THER 17(8):915-926. (2017) Link

Voko Z, Barra M, Molnar A, Kerpel-Fronius A, Bajzik G, Horvath I, Moizs M, Nagy B. Model concept of the health economic evaluation of low-dose CT lung cancer screening in Hungary. [in Hungarian] ORVOSI HETILAP 158.25. pp. 963–975. (2017) Link

Nemeth B, Molnar A, Akehurst R, Horvath M, Koczian K, Nemeth G, Gotze A, Voko Z. Quality-adjusted life year difference in patients with predominant negative symptoms of schizophrenia treated with cariprazine and risperidone. J COMP EFF RES. (2017) Link

Elek P, Harsanyi A, Zelei T, Csetneki K, Kalo Z. Policy objective of generic medicines from the investment perspective: The case of clopidogrel. HEALTH POLICY VOLUME 121, ISSUE 5, May 2017, pp. 558–565. Link

Elek P, Takacs E, Meresz G, Kalo Z. Implication of external price referencing and parallel trade on pharmaceutical expenditure: indirect evidence from lower-income European countries. HEALTH POLICY PLAN 1;32(3). 349-358. (2017) Link

Nemeth B, Csanadi M, Kalo Z.  Overview on the current implementation of health technology assessment in the healthcare system in Hungary. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 33:1 (2017), Page 1 of 6. Link

Kovacs G, Somogyvari Z, Maka E, Nagyjanosi L. Bedside ROP screening and telemedicine interpretation integrated to a neonatal transport system: Economic aspects and return on investment analysis. EARLY HUM DEV Feb 4;106-107:1-5. (2017) Link

Coyle K, Coyle D, Lester‐George A, West R, Nemeth B, Hiligsmann M, Trapero‐Bertran M, Leidl R, Pokhrel S. Development and application of an economic model (EQUIPTMOD) to assess the impact of smoking cessation. ADDICTION. (2017) Link

Huber MB, Präger M, Coyle K, Coyle D, Lester‐George A, Trapero‐Bertran M, Nemeth B, Cheung KL, Stark R, Vogl M, Pokhrel S. Cost‐effectiveness of increasing the reach of smoking cessation interventions in Germany: results from the EQUIPTMOD. ADDICTION. (2017) Link

Kalo Z, Voko Z, Ostor A, Clifton-Brown E, Vasilescu R , Battersby A, Gibson E. Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region. JOURNAL OF MARKET ACCESS & HEALTH POLICY 5:(1) Paper 1345580. 8 p. (2017) Link

 

2016

Kolasa K, Zah V, Kalo Z. The use of non-economic criteria in pricing and reimbursement decisions in Central and Eastern Europe: issues, trends and recommendations. EXPERT REV PHARMACOECON OUTCOMES RES 16(4). 483-488. (2016) Link

Voko Z, Zsolyom A, Jermendy Gy. Diabetes attributable mortality in Hungary in 2000-2009.[in Hungarian] LEGE ARTIS MEDICINAE 26:265-270. (2016) Link

Kovacs G, Zelei T, Voko Z. Comparison of efficacy and local tolerability of estradiol metered-dose transdermal spray to estradiol patch in a network meta-analysis. CLIMACTERIC. (2016) Link

Zelei T, Molnar MJ, Szegedi M, Kalo Z. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries. ORPHANET JOURNAL OF RARE DISEASES 11:(1) p. 72. (2016) Link

Inotai A, Csanadi M, Agh T. Real world data analysis to improve drug policy decision making in Central Eastern European countries. [in Hungarian] IME INTERDISZCIPLINARIS MAGYAR EGESZSEGUGY 15: 47-52. (2016) Link

Voko Z, Turi G, Zsolyom A. Cost-effectiveness of oral cancer screening in Hungary. [in Hungarian] ORVOSI HETILAP 157(29), 1161–1170. (2016) Link

Voko Z, Cheung KL, Jozwiak-Hagymasy J, Wolfenstetter S, Jones T, Munoz C, Evers SMAA, Hiligsmann M, de Vries H, Pokhrel S. Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey. HEALTH RESEARCH POLICY AND SYSTEMS 14:38. (2016) Link

Kalo Z, Voko Z, Akhras K, Kanavos P. Response to: Comment on the implications of external price referencing of pharmaceuticals in Middle East countries. EXPERT REVIEW OF PHARMACOECONOMICS AND OUTCOMES RESEARCH 16:(1) pp. 15-16. (2016) Link

Nagy B, Zsolyom A, Nagyjanosi L, Meresz G, Steiner T, Papp E, Dessewffy Z, Jermendy G, Winkler G, Kalo Z, Voko Z. Cost-effectiveness of a risk based secondary screening program of type 2 diabetes. DIABETES-METABOLISM RESEARCH AND REVIEWS 32:(7) pp. 710-729. (2016) Link

Glonti K, Pitter J, Csanadi M, Voko Z, McKee M. Health system factors associated with uptake of cancer screening: an overview of systematic reviews. EUROPEAN JOURNAL OF PUBLIC HEALTH 26:(suppl_1) p. 199. (2016) Link

Kalo Z, Voko Z, Clifton-Brown E, Vasilescu RS, David T, Gibson E, Begum N, Rao N. PMS94 - Impact of National Criteria and Healthcare System Characteristics on Access to Biologic Dmards in Rheumatoid Arthritis In Europe. VALUE IN HEALTH 19:(7) pp. A547-A548. (2016) ISPOR 19th Annual European Congress. Wien, Ausztria. Link

Zemplenyi AT, Mangel L, Kalo Z, Endrei D, Lohner S, Boncz I. Meta-analysis of the side-effect profiles of modern radiation therapies for patients with prostate cancer (Article in Hungarian). ORVOSI HETILAP 157(20):776-88. (2016) Link

Marsh K, IJzerman M, Thokala,P, Baltussen R, Boysen,M, Kalo,Z, Lonngren T, Mussen, F, Peacock S, Watkins J, Devlin N. Multiple Criteria Decision Analysis for Health Care Decision Making—Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force. VALUE HEALTH. (2016) Link

Kolasa K, Zwolinski KM, Hermanowski T, Kalo Z. Potential impact of the implementation of multiple-criteria decision analysis (MCDA) into the Polish pricing and reimbursement process of orphan drugs. ORPHANET JOURNAL OF RARE DISEASES 19(2). 125–137. (2016) Link

Zemplenyi AT, Mangel L, Kalo Z, Endrei D, Boncz I. A microcosting study of radiation therapy of localized prostate cancer. (in Hungarian) ORVOSI HETILAP 157. 12. 461-8. (2016) Link

Agh T, Kovacs G, Supina D, Pawaskar M, Herman BK, Voko Z, Sheehan DV. A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. Eating and Weight Disorders. EATING AND WEIGHT DISORDERS - STUDIES ON ANOREXIA, BULIMIA AND OBESITY. (2016) Volume 21, Issue 3, pp 353–364 Link

Agh T, Pawaskar M, Nagy B, Lachaine J, Voko Z. The cost-effectiveness of lisdexamfetamine dimesylate for the treatment of binge eating disorder in the United States. CLINICAL DRUG INVESTIGATION 36(4):305-312. (2016) Link

Bodnar R, Meszaros A, Olah M, Agh T. Inhaled antibiotics for the treatment of chronic Pseudomonas Aeruginosa infection in cystic fibrosis patients: challenges to treatment adherence and strategies to improve outcomes. PATIENT PREFERENCE AND ADHERENCE 10:183-193. (2016) Link

Cheung KL, Evers SM, Hiligsmann M, Voko Z, Pokhrel S, Jones T, Muñoz C, Wolfenstetter SB, Jozwiak-Hagymasy J, de Vries H. Understanding the stakeholders' intention to use economic decision-support tools: A cross-sectional study with the tobacco return on investment tool. HEALTH POLICY Jan;120(1):46-54. (2016) Link

Thokala P, Devlin N, Marsh K, Baltussen R, Boysen M, Kalo Z, Longrenn T, Mussen F, Peacock S, Watkins J, Ijzerman M. Multiple Criteria Decision Analysis for Health Care Decision Making-An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force. VALUE HEALTH 19. 1. 1-13. (2016) Link

Kalo Z, Gheorghe A, Huic M, Csanadi M, Kristensen FB. HTA Implementation Roadmap in Central and Eastern European Countries. HEALTH ECON Feb;25 Suppl 1:179-92. (2016) Link

 

2015

Mandrik O, Knies S, Kalo Z, Severens JL. Reviewing transferability in economic evaluations originating from Eastern Europe. INT J TECH ASSESS HEALTH CARE31. 6. 434–441. (2015) Link

Drummond M, Augustovski F, Kalo Z, Yang BM, Pichon-Riviere A, Bae EZ, Kamal-Bahl S. Challenges faced in transferring economic evaluations to middle income countries. INT J TECHNOL ASSESS HEALTH CARE 31. 6. 442-8. (2015) Link

Pitter J, Jozwiak A, Martos E, Kalo Z, Voko Z. Next steps to evidence-based food safety risk analysis: opportunities for health technology assessment methodology implementation. STUDIES IN AGRICULTURAL ECONOMICS 117. 155-161. (2015) Link

Agh T, Bodnar R, Olah M, Meszaros A. Adherence to Inhaled Antibiotics for The Treatment of Chronic Pseudomonas Aeruginosa Infection In Patients With Cystic Fibrosis: A Systematic Literature Review. VALUE HEALTH. (2015) Link

Bartfai Z, Agh T, Domotor P, Bartfai L, Meszaros A. Therapeutic opportunities derived from clinical differences among inhaled corticosteroids. [in Hungarian] MEDICINA THORACALIS5:339-344. (2015)

Oyebode O, Garrett Z, George E, Cangini A, Muscolo LA, Warren S, Nemeth B, Foldesi C, Heislerova M, Gajdosova E. Evidence requirements for reimbursement of pharmaceuticals across Europe. INT J TECHNOL ASSESS HEALTH CARE Jan;31(1-2):59-67. (2015) Link

Gyulai A, Nagy A, Pataki V, Tonte D, Adany R, Voko Z. Survey of participation in Organised Cervical Cancer-Screening programme in Hungary. CENTRAL EUROPEAN JOURNAL OF PUBLIC HEALTH 23:(4) pp. 360-364. (2015) Link

Kind P, Voko Z. A national eq-5d value set for Hungary: a model methodology? VALUE IN HEALTH 18:(7) p. A738. (2015) Link

Pawaskar M, Voko Z., Agh T, Sheehan D V, McElroy S L, Radewonuk J, Meresz G, Herman B K, Gasior M. Longitudinal modeling the effect of lisdexamfetamine dimesylate and changes in binge eating frequency on disability in patients with binge eating disorder. VALUE IN HEALTH 18:(7) p. A407. (2015) Link

Pitter J G, Voko Z., Jozwiak A. Cost-Utility Analysis of Potential Campylobacter Control Measures in the Food Chain of Indoor Broiler Chicken in the EU. VALUE IN HEALTH 18:(7) p. A649. (2015) Link

Kalo Z, Alabbadi I, Al Ahdab OG, Alowayesh M, Elmahdawy M, Al-Saggabi AH, Tanzi VL, Al-Badriyeh D, Alsultan HS, Ali FM, Elsisi GH, Akhras KS, Voko Z, Kanavos P. Implications of external price referencing of pharmaceuticals in Middle East countries. EXPERT REV PHARMACOECON OUTCOMES RES Dec;15(6):993-8. (2015) Link

Inotai A, Abonyi-Toth Z, Rokszin G, Voko, Z. Prognosis, Cost, and Occurrence of Colorectal, Lung, Breast, and Prostate Cancer in Hungary. VALUE IN HEALTH REGIONAL ISSUES 7:1-8. (2015) Link

Sebestyen A, Mester S, Voko Z, Gajdacsi J, Cserhati P, Speer G, Patczai B, Warta V, Bodis J, Horvath C, Boncz I. Wintertime surgery increases the risk of conversion to hip arthroplasty after internal fixation of femoral neck fracture. OSTEOPOROS INT 26(3):1109-1117. (2015) Link

Agh T, Peterne D, Bartfai Z., Inotai A, Fujsz E, Meszaros A. (2015) Relationship between medication adherence and health related quality of life in patients with COPD: a systematic review. RESPIRATORY CARE 60:297-303. (2015) Link

Kalo Z, Holtorf AP, Alfonso-Cristancho R, Shen J, Agh T, Inotai A, Brixner D. Need for Multicriteria Evaluation of Generic Drug Policies. VALUE IN HEALTH 18. 346-351. (2015) Link

Nagy B: Improving the allocation of health care resources in Poland. WORLD HEALTH ORGANIZATION REGIONAL OFFICE FOR EUROPE. Copenhagen (2015) Link

Jozwiak-Hagymasy J, Voko Z: Use of inhalation devices in asthma and chronic obstructive pulmonary disease: a Delphi consensus panel [in Hungarian] IME 14:1 48:53. (2015) Link

Voko Z, Beran D, Pusztai Zs, Bak Pedersen H, Evetovits T, Szigeti Sz. Better non-communicable disease outcomes: challenges and opportunities for health systems. Hungary Country Assessment: Focus on diabetes 2014. WHO REGIONAL OFFICE FOR EUROPE. (2015) Link

Agh T, Kovacs G, Pawaskar M, Supina D, Inotai A, Voko Z. (2015) Epidemiology, health-related quality of life and economic burden of binge eating disorder: a systematic literature review. EATING AND WEIGHT DISORDERS 20:1-12. (2015) Link

Pawaskar M , Agh T , Radewonuk J , Voko Z , McElroy S L , Herman B K , Gasior M. Longitudinal modeling of the relationship between lisdexamfetamine dimesylate and health-related quality of life in adults with moderate to severe binge eating disorder. VALUE IN HEALTH 18:(7) p. A407. (2015) Link

 

2014

Lorenzovici L, Szekely A, Agh T, Vamossy I, Kelemen LJ, Finta H, Kalo Z. Economic Evaluation of Ulipristal Acetate for the Treatment of Patients With Moderate and Severe Symptoms of Uterine Fibroids in Romania. VALUE HEALTH. (2014) Link

Meresz G., Foldesi Cs., Nagyistok Sz., Vincziczki A.: Changes on the market of publications and a dynamising health economic researcher community [in Hungarian]. EGESZSEGUGYI GAZDASAGI SZEMLE 2014/2-3, p36-41. Link

Pokhrel S, Evers S, Leidl R, Trapero-Bertran M, Kalo Z, Vries Hd, Crossfield A, Andrews F, Rutter A, Coyle K, Lester-George A, West R, Owen L, Jones T, Vogl M, Radu-Loghin C, Voko Z, Huic M, Coyle D. EQUIPT: protocol of a comparative effectiveness research study evaluating cross-context transferability of economic evidence on tobacco control. BMJ OPEN Nov 24;4(11):e006945. 2014. Link

Agh T, Pawaskar M, Kovacs G, Kalo Z, Supina D, Voko Z. The humanistic and economic burden of bulimia nervosa and binge eating disorder: A systematic literature review. VALUE IN HEALTH 17:(3) p. A213. (2014) Link

Gregory V, Barbeau M, Machnicki G, Voko Z, Heisel O, Keown P. Real world research in latin america: oportunities, sources and barriers. VALUE IN HEALTH 17:(3) p. A188. (2014) Link

Inotai A, Abonyi-Toth Z, Rokszin G, Voko Z. Occurrence, survival and annual cost of colorectal-, breast-, prostate- and lung cancer in hungary. VALUE IN HEALTH 17:(7) p. A553. (2014) Link

Zsolyom A, Nagy B, Dessewffy Z, Steiner T, Kalo Z, Voko Z. Cost-effectiveness of the introduction of a risk stratified population screening for type 2 diabetes in hungary. VALUE IN HEALTH 17:(3) p. A259. (2014) Link

Zsolyom A, Nagy B, Nagyjanosi L, Dessewffy Z, Steiner T, Kalo Z, Voko Z. Cost-effectiveness of the introduction of a national adherence program for type 2 diabetes in hungary. VALUE IN HEALTH 17:(7) p. A358. (2014) Link

Kalo Z, Antal J, Penzes M, Pozsgay C, Szepezdi Z, Nagyjanosi L. Contribution of clinical trials to gross domestic product in Hungary. CROAT MED J Oct 30;55(5):446-51. (2014) Link

Kolasa K, Kalo Z, Hornby E. Pricing and reimbursement frameworks in Central Eastern Europe: a decision tool to support choices. EXPERT REV PHARMACOECON OUTCOMES RES15. 1. 145-55. (2014) Link

Strain WD, Cos X, Hirst M, Vencio S, Mohan V, Voko Z, Yabe D, Bluher M, Paldanius PM. Time to do more: Addressing clinical inertia in the management of type 2 diabetes mellitus. DIABETES RES CLIN PRACT. (2014) Link

Voko Z, Nemeth R, Nagyjanosi L, Jermendy Gy, Winkler G, Hidvegi T, Kalotai Z, Kalo Z. Mapping the Nottingham Health Profile onto the Preference-Based EuroQol-5D Instrument for Patients with Diabetes. VALUE IN HEALTH REGIONAL ISSUES 4. 1. 31-36. (2014) Link

Elsisi GH, Eldessouki R, Kalo Z, Elmazar MM, Taha AS, Awad BF, El-Hamamsy MH. Cost-Effectiveness of the Combined Use of Warfarin and Low-Dose Aspirin versus Warfarin Alone in Egyptian Patients with Aortic Valve Replacements: A Markov Model. VALUE IN HEALTH REGIONAL ISSUES4. 1. 24-30. (2014) Link

Kalo Z, Boncz I, Dank M, Koczian K, Molnar MJ, Nagy B, Nemeth Gy, Pitter J, Zelei T. Health Economic Aspects of Personalized Medicine: Do Personalized Technologies Reduce Health Expenditure? [in Hungarian] IME13. 5. 41-45. (2014) Link

Kwong D, Ferrario A, Adamski J, Inotai A, Kalo Z. Managing the Introduction of New and High-Cost Drugs in Challenging Times: The Experience of Hungary and Poland. EUROHEALTH 20. 2. 25-28. (2014) Link

Adany R; Voko Z. Hungarian public health - ups and downs in the last 20 years. EU J PUB HEALTH (2014) Link

Inotai A, Petrova G, Vitezic D, Kalo,Z. Benefits of investment into modern medicines in Central Eastern European countries. EXPERT REV PHARMACOECON OUTCOMES RES 14. 1. 71-79. (2014) Link

Kovacs G, Kalo Z, Jahnz-Rozyk K, Kyncl J, Csohan A, Pistol A, Leleka M, Kipshakbaev R, Durand L, Macabeo B. Medical and economic burden of influenza in the elderly population in central and eastern European countries. HUMAN VACCINES AND IMMUNOTHERAPEUTICS  10. 2. 1-13. (2014) Link

Nagy B, Timar G, Jozwiak-Hagymasy J, Kovacs G, Meresz G, Vamossy I, Agh T, Laszlo A, Voko Z, Kalo Z. The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. EUR J OBSTET GYNECOL REPROD BIOL 175. 75-81. (2014) Link

 

2013

Szabo L, Jackowska T, Kalo Z, Kulcsar A, Meszner Zs, Molnar Zs, Wysocki J, Wutzler P, Kormos-Tasi J, Sauboin C. Varicella vaccination in Hungary and Poland: optimization of public benefits from prophylaxis technologies in the time of austerity. NEW MEDICINE 3. 97-102. (2013) Link

Zsolyom A, Meresz G, Nagyjanosi L, Nagyistok S, Nagy B, Kalo Z, Voko Z. PRM87 - External Validation of the Syreon Diabetes Model. VALUE IN HEALTH 16:(7) p. A590. (2013) Link

Boncz I, Kalo Z, Mohamed Ibrahim MIB, Greenberg D. Further steps in the development of pharmacoeconomics, outcomes research, and health technology assessment in central and Eastern Europe, Western Asia, and Africa. VALUE IN HEALTH REGIONAL ISSUES  2. 2. 169-170. (2013)

Voko Z, Nemeth R, Dank M, Nagy-Erdei Zs, Kalo Z, Geczi L: Mapping the cancer-specific EORTC QLQ-BR23 onto the preference-based EuroQol-5D instrument. JHPOR. (2013) 

Voko Z, Inotai A, Horvath Cs, Bors K, Speer G, Kalo Z: Quality of Life of Patients With Osteoporosis In Hungary. [in Hungarian] LAM KID 3(4). (2013) Link

Orosz E, Meresz G, Nagy B: Investment to human capital: fallback from the developed countries? [in Hungarian] EDUCATIO. Volume 22, Number 2, 2013., p159-176. Link

Meresz G, Nemeth B, Sinkovits B: VII. IME-META Advanced Training and Conference on Health Economics: „Is the crisis an opportunity or a curse?” Conference Report. ACTA OECONOMICA Volume 63, Number 3, September 2013., p377-381. Link

Kalo Z, Annemans L, Garrison LP: Differential pricing of new pharmaceuticals in lower income European countries. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH 13. 6. 735-41. (2013) Link

Elsisi GH, Kalo Z, Eldessouki R, Elmahdawy MD, Saad A, Ragab S, Elshalakani AM, Abaza S: Recommendations for reporting pharmacoeconomic evaluations in Egypt. VALUE IN HEALTH REGIONAL ISSUES. 2. 2. 319 -327. (2013) Link

Kalo Z, Bodrogi J, Boncz I, Dozsa Cs, Jona G, Kovi R, Pasztelyi Z, Sinkovits B: Capacity Building for HTA Implementation in Middle-Income Countries: The Case of Hungary. VALUE IN HEALTH REGIONAL ISSUES 2. 2. 264-266. (2013) Link

Szabo RP, Klenk N, Balla J, Asztalos L, Szabo L, Voko Z: Prognosis of dialysed patients after kidney transplant failure. KIDNEY BLOOD PRESS RES 37:151-157. (2013) Link

Agh T, Meszaros A, Bartfai Z: Quality of life and adherence in chronic obstructive pulmonary disease [in Hungarian]. MEDICAONLINE Link

 

2012

Borsos G, Voko Z, Gredes T, Kunert-Keil C, Vegh A: Tooth movement using palatal implant supported anchorage compared to conventional dental anchorage. ANN ANAT. (2012) Link

Inotai A, Agh T, Meszaros A: Quality of life, utility and health burden in asthma, chronic obstructive pulmonary disease and rheumatoid arthritis. INTERNATIONAL JOURNAL OF PERSON CENTERED MEDICINE 2: 505-510. (2012) Link

Inotai A, Kalo Z: Risk sharing methods in middle income countries [in Hungarian]. ACTA PHARM HUNG 82: 43-52. (2012) Link

Inotai A, Meszaros A: Determinants of NSAID choice in rheumatoid arthritis - a drug utilization study. ACTA POL PHARM 69: 773-777. (2012) Link

Inotai A, Nagy B, Kalo Z: Biosimilars and evidence based decision making in Central Eastern European countries. [in Hungarian] ORVOSTOVABBKEPZO SZEMLE 19: 69-73. (2012) Link

Inotai A, Nuijten M, Roth E, Hegazi R, Kalo Z: Modelling the burden of disease associated malnutrition. e-SPEN JOURNAL 7. e196-e204. (2012) Link

Inotai A, Pekli M, Jona G, Nagy O, Remak E, Kalo Z: Attempt to increase the transparency of fourth hurdle implementation in Central-Eastern European middle income countries: publication of the critical appraisal methodology. BMC HEALTH SERV RES 21. 12. 1. 332. (2012) Link

Kalo Z, Abonyi-Toth Zs, Bartfai Z, Voko Z: Pitfalls associated with the therapeutic reference pricing practice of asthma medication, BMC PULMONARY MEDICINE 20. 12. 1. 35. (2012) Link

Kalo Z, Boncz I, Inotai A: Implications of economic crisis on health care decision-making in Hungary: An opportunity to change? JOURNAL OF HEALTH POLICY AND OUTCOMES RESEARCH  1. 20 -26. (2012) Link

Kalo Z, Landa K, Doležal T, Voko Z: Transferability of NICE recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. EUROPEAN JOURNAL OF CANCER CARE  21. 4. 442-449. (2012) Link

Kalo Z, Meresz G, Mezei D, Totth A, Inotai A: The grounding and implications of Szell Kalman Plan [in Hungarian]. IME AZ EGESZSEGUGYI VEZETOK SZAKLAPJA 11:6 12-16. (2012) Link

Kalo Z, Nagy B: Methodological questions in assessing the cost effectiveness of prevention programs. [in Hungarian] EGESZSEGUGYI GAZDASAGI SZEMLE 50:1 29-31. (2012) Link

Kolasa K, Kalo Z, Zah V, Dolezal T: The role of HTA in the process of implementation of EU Transparency Directive: a relevant experience from Central Eastern European countries. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH  12. 3. 283-7. (2012) Link

Meresz G, Kalo Z, Tabak A: Cost minimisation analysis of basal insulin analogues for treatment of type 2 diabetes. [in Hungarian] LEGE ARTIS MEDICINAE 22(12):669–676. (2012) Link

Nagy B, Nagyjanosi L, Nagyistok Sz, Jozwiak-Hagymasy J, Meresz G, Papp E, Dessewffy Z, Jermendy GY, Winkler G, Kalo Z, Voko Z: Health economic modell to assess the screening, treatment and management strategies of diabetes. [in Hungarian] DIABETOLOGIA HUNGARICA 20.4 p.245-255. (2012) Link

Nagy B, Gaspar I, Papp A, Bene Z, Nagy B, Voko Z, Balla G: Efficacy of methylprednisolone in children with severe community acquired pneumonia. PEDIATRIC PULMONOLOGY Volume 48, Issue 2 February 2013 Pages 168–175. (2012) Link

Nagy B, Meresz G: Role of risk-sharing in health care. [in Hungarian] EGESZSEGUGYI GAZDASAGI SZEMLE November 1; 50(4): 42-48. (2012) Link

Papp K, Vegh P, Hobor R, Szittner Z, Voko Z, Podani J, Czirjak L, Prechl J: Immune Complex Signatures of Patients with Active and Inactive SLE Revealed by Multiplex Protein Binding Analysis on Antigen Microarrays. PLOS ONE;7(9):e44824. (2012) Link

Petrovski B E, Pataki V, Jenei T, Adany R, Voko Z: Selenium levels in men with liver disease in Hungary. JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY 26:(1) pp. 31-35. (2012) Link

Szigethy E, Szeles G, Horvath A, Hidvegi T, Jermendy G, Paragh G, Blasko G, Adany R, Voko Z: Epidemiology of the metabolic syndrome in Hungary PUBLIC HEALTH 126:(2) pp. 143-149. (2012) Link

Voko Z, Nagyjanosi L, Kalo Z: Cost-effectiveness of adding vaccination with the AS04-adjuvanted human papillomavirus 16/18 vaccine to cervical cancer screening in Hungary, BMC PUBLIC HEALTH 12. 1. 924. (2012) Link

Voko Z, Nagyjanosi L, Margitai B, Kovi R, Toth Z, Laszlo D, Kalo Z: Modeling cost-effectiveness of cervical cancer screening in Hungary. VALUE IN HEALTH 15. 39-45. (2012) Link

Walter S, Mackenbach J, Voko Z, Lhachimi S, Ikram MA, Uitterlinden AG, Newman AB, Murabito JM, Garcia ME, Gudnason V, Tanaka T, Tranah GJ, Wallaschofski H, Kocher T, Launer LJ, Franceschini N, Schipper M, Hofman A, Tiemeier H: Genetic physiological, and lifestyle predictors of mortality in the general population. AMERICAN JOURNAL OF PUBLIC HEALTH 102:(4) pp. e3-10. (2012) Link

Meszaros A, Agh T, Bartfai Z, Orosz M: Quality of life decrement and health burden in asthma and COPD [in Hungarian]. MEDICINA THORACALIS  65: 219. (2012)

Kalo Z, Landa K, Doležal T, Voko Z. Transferability of National Institute for Health and Clinical Excellence recommendations for pharmaceutical therapies in oncology to Central-Eastern European countries. EUROPEAN JOURNAL OF CANCER CARE 21:(4) pp. 442-449. (2012) Link

Meresz G, Nagyjanosi L, Nagy B, Dessewffy Z, Voko Z, Kalo Z. Internal validation of the syreon diabetes model. VALUE IN HEALTH 15:(7) p. A475. (2012) Link

 

2011

Nemeth J, Nagyjanosi L, Nagyistok Sz, Tolnayne Csattos M, Szabone Berta I, Kincse E, Szulyak E, Boer I, Hundzsa Gy, Kalo Z, Berta A: Societal burden of blindness in Hungary [in Hungarian] LAM (Lege Artis Medicinæ);21(10). (2011) Link

Nagy B, Nagyjanosi L, Nagyistok S, Hagymasy JJ, Dessewffy Z, Kalo Z, Voko Z. Development of a health economic model to compare the prevention, treatment and management strategies of type 2 diabetes. VALUE IN HEALTH 14:(7) pp. A486-A487. (2011) Link

Nagyjanosi L, Martos E, Bodonyi D, Voko Z. Health-economic impact of the hungarian salt intake reduction program. VALUE IN HEALTH 14:(7) p. A376. 1 p. (2011) Link

Kalo Z, Abonyi-Toth Z, Bartfai Z, Timar G, Voko Z. Pitfalls in therapeutic reference pricing practice of the medication of asthma. VALUE IN HEALTH 13:(7) p. A321. (2011) Link

Agh T, Inotai A, Meszaros A: Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. RESPIRATION. (2011) Link

Gorog K, Pattenden S, Antova T, Niciu E, Rudnai P, Scholtens S, Splichalova A, Slotova K, Voko Z, Zlotkowska R, Houthuijs D: Maternal Smoking During Pregnancy and Childhood Obesity: Results from the CESAR Study. MATERNAL CHILD HEALTH JOURNAL 15: pp. 985-992. (2011) Link

Inotai A, Meresz G, Kalo Z: Assessment of Hungarian pharmaceutical expenditures with respect to Szell Kalman Plan [in Hungarian]. EGESZSEGUGYI GAZDASAGI SZEMLE 49: 9-13. (2011) Link

Inotai A, Rojkovich B, Fulop A, Jaszay E, Agh T, Meszaros A: Health-related quality of life and utility in patients receiving biological and non-biological treatments in rheumatoid arthritis. RHEUMATOL INT. (2011) Link

Kalo Z, Voko Z: Health technology assessment: a European collaboration. Meeting report. EXPERT REV. PHARMACOECONOMICS OUTCOMES RES 11.1. 41-43. (2011) Link

Losonczy G, Fekete A, Voko Z, Takacs L, Kaldi I, Ajzner E, Kasza M, Vajas A, Berta A, Balogh I: Analysis of complement factor H Y402H, LOC387715, HTRA1 polymorphisms and ApoE alleles with susceptibility to age-related macular degeneration in Hungarian patients ACTA OPHTHALMOLOGICA 89:(3) pp. 255-262. (2011) Link

Nagy B, Brennan A, Brandtmuller A, Thomas S, SD Sullivan, R Akehurst: Assessing the cost-effectiveness of the rivastigmine transdermal patch for Alzheimer’s disease in UK using MMSE- and ADL-based models. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY 26:5 483-94. (2011) Link

Ohmann C, Kuchinke W, Canham S, Lauritsen J, Salas N, Schade-Brittinger C, Wittenberg M, McPherson G, McCourt J, Gueyffier F, Lorimer A, Torres F, Collaborator: Voko Z: Standard requirements for GCP-compliant data management in multinational clinical trials. TRIALS 12: p. 85. (2011) Link

Papp K, Vegh P, Hobor R, Szittner Z, Voko Z, Podani J, Koranyi KL, Czirjak LK, Prechl J: Functional serum antibody profiles in autoimmune disease diagnostics MOLECULAR IMMUNOLOGY 48:(14) p. 1732. (2011) Link

Petrovski B E, Szeles G, Melles M, Pataki V, Kardos L, Jenei T, Adany R, Voko Z: Behaviour does not fully explain the high risk of chronic liver disease in less educated men in Hungary EUROPEAN JOURNAL OF PUBLIC HEALTH 21:(5) pp. 662-666. (2011) Link

Rojkovich B, Inotai A: Cardiovascular safety of nonsteroidal antiinflammatory drugs [in Hungarian]. LEGE ARTIS MEDICINAE 21: 123-125. (2011) Link

Szabo RP, Asztalos L, Szabo L, Balla J, Voko Z: Validation of a prognostic function for renal transplant recipients in Hungary JOURNAL OF NEPHROLOGY 24:(5) pp. 619-624. (2011) Link

Voko Z: Potentials of payers' databases for pharmacoepidemiological investigations. BASIC CLINICAL PHARMACOLOGY TOXICOLOGY 109:(1) p. 21. 1 p. (2011)

Voko Z, de Brouwer S, Lubsen J, Danchin N, Otterstad JE, Dunselman PH, Kirwan BA: Long-term impact of secondary preventive treatments in patients with stable angina. EUROPEAN JOURNAL OF EPIDEMIOLOGY 26: pp. 375-383. (2011) Link

Meszaros A, Szabo L, Agh T, Fujsz E, Bartfai Z: Measurement of health related quality of life and asthma control in Hungary [in Hungarian]. TUDOGYOGYASZAT 5: 28-31. (2011)

 

2010

Agh T, Meszaros A: Compliance and persistence with medications for chronic obstructive pulmonary disease. CLINICAL AND EXPERIMENTAL MEDICAL JOURNAL 4: 15-22. (2010) Link

Bodrogi J, Kalo Z: Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development. BR J PHARMACOL 159. 7. 1367-73. (2010) Link

Inotai A, Hanko B, Meszaros A: Trends in the non-steroidal anti-inflammatory drug market in six Central-Eastern European countries based on retail information. PHARMACOEPIDEMIOL DRUG SAF 19: 183-190. (2010) Link

Inotai A, Kalo Z: The assessment of innovation and the R&D&I strategy of public health care sector [in Hungarian]. EGESZSEGUGYI GAZDASAGI SZEMLE  48: 33-38. (2010) Link

Inotai A, Meresz G, Kalo Z: Assessment of the pharmaceutical expenditure in Hungary [in Hugarian]. ACTA PHARM HUNG 80: 162-172. (2010) Link

Inotai A, Rojkovich B, Meszaros A: The assessment of oral NSAID use in patients with rheumatoid arthritis in Hungary-a cross sectional non interventional study. [in Hungarian] ACTA PHARM HUNG 80: 47-54. (2010) Link

Kalo Z, Kiss Z, Gerendy P, Nagyjanosi L, Voko Z. Cost of Renal Replacement Therapy in Hungary: 2749. TRANSPLANTATION 90: p. 735. (2010) Link

Voko Z, Nagyjanosi L, Kalo Z. Cost-effectiveness analysis of adding hpv vaccination to cervical cancer screening program in hungary. VALUE IN HEALTH 13:(7) pp. A270-A271. (2010) Link

Kuchinke W, Ohmann C, Yang Q, Salas N, Lauritsen J, Gueyffier F, Leizorovicz A, Schade-Brittinger C, Wittenberg M, Voko Z, Gaynor S, Cooney M, Doran P, Maggioni A, Lorimer A, Torres F, McPherson G, Charwill J, Hellstrom M, Lejeune S: Heterogeneity prevails: the state of clinical trial data management in Europe - results of a survey of ECRIN centres TRIALS 11: Paper 79. (2010) Link

Nagy B: Resource allocation in Hungarian health care - Is there a missing link? [in Hungarian]. KOZGAZDASAGI SZEMLE 57:4 337-353. (2010) Link

Voko Z, Danchin N, de Brouwer S, Kirwan BA, Poole-Wilson PA, Lubsen J: Correlates of coronary angiography in patients with stable angina and geographical differences in its utilisation: The ACTION experience INTERNATIONAL JOURNAL OF CARDIOLOGY 138:(1) pp. 56-62.(2010) Link

Agh T, Bodnar R, Agh L: The importance of quality of life monitoring in the management of asthma [in Hungarian]. MEDICUS UNIVERSALIS 43: 179-181. (2010)

Orosz M, Galffy G, Kovacs D, Agh T, Meszaros A: Quality of life, possible influential factors of asthmatics and COPD patients [in Hungarian]. MEDICINA THORACALIS  63: 277-283. (2010)

Agh T, Meszaros A: Pharmacoeconomic impact of compliance [in Hungarian]. ACTA PHARMACEUTICA HUNGARICA 80: 75-80. (2010) Link

Orosz M, Galffy G, Agh T, Kovacs D, Meszaros A: The everyday life of patients with asthma or COPD. [in Hungarian]. MEDICINA THORACALIS 63: 181-182. (2010)

Agh T, Bartfai Z, Meszaros A: Relation of adherence to quality of life in COPD patients. [in Hungarian]. MEDICINA THORACALIS  63: 197. (2010)

 

2009

Inotai A, Kalo Z Meszaros A: Decision analytic modeling and their impact on health care decision making. [in Hungarian] ACTA PHARM HUNG 79: 63-69. (2009) Link

Inotai A, Meszaros A: Economic evaluation of NSAID strategies in rheumatoid arthritis. Cost-effectiveness of celecoxib in Hungary. INT J TECHNOL ASSESS HEALTH CARE 25: 190-195. (2009) Link

Nagy B, Brandtmuller A, Dozsa Cs: The Redistributive Role of the State in the British and Dutch Health Care Market. Is there another Way? [in Hungarian] TARSADALOMKUTATAS (SOCIAL SCIENCE RESEARCH) 27: 2117-2138. (2009) Link

Nagy B, Brennan A, Skultety L, Nagy J, Szentesi A, Dessewffy Z, Kalotai Z: The cost effectiveness of rivastigmine transdermal patch in the management of patients with mild and moderate Alzheimer’s disease [in Hungarian]. IME 8:3 40-45. (2009) Link

Voko Z, Csepe P, Nemeth R, Kosa K, Kosa Zs, Szeles Gy, Adany R: Does socioeconomic status fully mediate the effect of ethnicity on the health of Roma people in Hungary? JOURNAL OF EPIDEMIOLOGY AND COMMUNITY HEALTH 63:(6) pp. 455 460. (2009) Link

Voko Z, Nagyjanosi L, Kalo Z: Direct health care costs of diabetes mellitus in Hungary [in Hungarian], LEGE ARTIS MEDICIANE 19(12):775-780. (2009) Link

Agh T, Meszaros A: Compliance and persistence with medication in chronic obstructive pulmonary disease [in Hungarian]. ORVOSI HETILAP 150: 1497-1502. (2009) Link

Agh T, Agh L: The significance of medication compliance and persistence in hypertension, diabetes mellitus and dyslipidaemia [in Hungarian]. MEDICUS UNIVERSALIS  42: 3-6. (2009) Link

 

2008

Bhalla A, Grieve R, Rudd AG, Wolfe CD, BIOMED II ESSC, 44 Authors, Voko Z, Ovary C: Stroke in the Young: Access to Care and Outcome; A Western Versus Eastern European Perspective JOURNAL OF STROKE AND CEREBROVASCULAR DISEASES 17:(6) pp. 360-365. (2008) Link

Inotai A, Meszaros A: Cost effectiveness of celecoxib in rheumatoid arthritis [in Hungarian], IME 7: 48-50. (2008) Link

Inotai A, Vincze Z: Cost study of NSAID use in rheumatoid arthritis based on recent therapeutic protocols [in Hungarian], ACTA PHARM HUNG 78: 79-86. (2008) Link

Nagy B, Brandtmuller A: Implementing risk adjusted capitation payments with health care reforms in Hungary. COMPETITIO  8:2 147-160. (2008) Link

Nagy B, Rakonczai P, Gulacsi L: Application of statistical methods to calculate capitation payments in the Hungarian health care. [in Hungarian] STATISZTIKAI SZEMLE (HUNGARIAN STATISTICAL REVIEW) 86:4 321-341. (2008) Link

Nagy B, Rakonczai P, Sipos J: Predicting health care expenditures with demographic characteristics for designing capitation payments in Hungary [in Hungarian]. IME  7:Egeszseg-gazdasagtani kulonszam 5-9. (2008) Link

Takemoto SK, Arns W, Bunnapradist S, Garrison LP, Guirado L, Kalo Z, Oniscu G, Opelz G, Scolari MP, Stefoni S, Yaqoob M, Brennan DC: Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. TRANSPLANTATION 86.1. 18-25. (2008) Link

 

 

TODAY'S RESEARCH FOR TOMORROW'S HEALTH

Syreon Research Institute: 1142 Budapest, Mexikoi str. 65/A.

E-mail: info@syreon.eu